NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis $1.34 -0.01 (-0.74%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.34 0.00 (0.00%) As of 02/21/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Salarius Pharmaceuticals Stock (NASDAQ:SLRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SLRX alerts:Sign Up Key Stats Today's Range$1.31▼$1.3750-Day Range$1.22▼$3.6752-Week Range$1.22▼$7.20Volume46,957 shsAverage Volume68,781 shsMarket Capitalization$2.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.Read More… Salarius Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreSLRX MarketRank™: Salarius Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Salarius Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Salarius Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Salarius Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSalarius Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Salarius Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.25% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 93.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSalarius Pharmaceuticals does not currently pay a dividend.Dividend GrowthSalarius Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.25% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 93.81%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows4 people have added Salarius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.38% of the stock of Salarius Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.Read more about Salarius Pharmaceuticals' insider trading history. Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SLRX Stock News HeadlinesSalarius resumes trial for MDS and CMML treatmentFebruary 3, 2025 | msn.comSalarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic CancersFebruary 3, 2025 | globenewswire.comThe FED is losing the war on inflation It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…February 22, 2025 | WealthPress (Ad)Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger AgreementJanuary 15, 2025 | finanznachrichten.de$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRXJanuary 14, 2025 | globenewswire.comSalarius, Decoy Therapeutics enter definitive merger agreementJanuary 13, 2025 | markets.businessinsider.comSalarius Pharmaceuticals Announces Merger With Decoy Therapeutics To Advance CancerJanuary 13, 2025 | markets.businessinsider.comHouston's Salarius Pharmaceuticals to merge with Gates Foundation-backed co., focus on Covid-19 treatmentJanuary 13, 2025 | bizjournals.comSee More Headlines SLRX Stock Analysis - Frequently Asked Questions How have SLRX shares performed this year? Salarius Pharmaceuticals' stock was trading at $1.84 at the beginning of 2025. Since then, SLRX stock has decreased by 27.2% and is now trading at $1.34. View the best growth stocks for 2025 here. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its earnings results on Friday, August, 9th. The company reported ($2.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($53.60) by $51.23. When did Salarius Pharmaceuticals' stock split? Salarius Pharmaceuticals's stock reverse split before market open on Monday, June 17th 2024. The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Salarius Pharmaceuticals' major shareholders? Top institutional investors of Salarius Pharmaceuticals include Concourse Financial Group Securities Inc.. Insiders that own company stock include David J Arthur, Mark J Rosenblum, Arnold C Hanish and William K Mcvicar. View institutional ownership trends. How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/09/2024Today2/22/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees20Year Founded2011Profitability EPS (Most Recent Fiscal Year)($8.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-140.28% Return on Assets-105.76% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.74 per share Price / Book0.12Miscellaneous Outstanding Shares1,580,000Free Float1,562,000Market Cap$2.12 million OptionableNot Optionable Beta0.84 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:SLRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
